Hemophilia A

- Patient is enrolled in the BAY94-9027 extension studies or is within 3 months of having completed participation in the BAY94-9027 extension studies;
- Patient allocated to Arm 2, Arm 3 or Arm 4 of BAY94-9027 extension studies.
 -- Arm 2 Prophylaxis treatment of BAY94-9027; 2 infusions per week during the extension study
 --Arm 3 Prophylaxis treatment of BAY94-9027; infusion every 5 days during the extension study
 --Arm 4 Prophylaxis treatment of BAY94-9027; every 7 days during the extension study
- Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study;
- Patient must be willing and able to participate in a telephone interview lasting up to 30 minutes;
- Patient must have sufficient cognitive and linguistic capacities to allow them to actively participate in an interview lasting 30 minutes.

- Patient is part of Arm 1: On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds;
- Patient is unlikely to comply with the study protocol (e.g. uncooperative attitude) or unlikely to complete the study for any reason in the opinion of the recruiter;
- Patient has great difficulty hearing or reading;
- Patient has any significant comorbid condition (including uncontrolled psychiatric conditions) that might limit or interfere with their ability to talk about their Hemophilia A and participate in the study;
- Patient has severe neurological or cognitive deficits that might affect their ability to participate in an interview.